KR102381790B1 - 보체 인자 b의 조절자 - Google Patents

보체 인자 b의 조절자 Download PDF

Info

Publication number
KR102381790B1
KR102381790B1 KR1020167009610A KR20167009610A KR102381790B1 KR 102381790 B1 KR102381790 B1 KR 102381790B1 KR 1020167009610 A KR1020167009610 A KR 1020167009610A KR 20167009610 A KR20167009610 A KR 20167009610A KR 102381790 B1 KR102381790 B1 KR 102381790B1
Authority
KR
South Korea
Prior art keywords
delete delete
certain embodiments
wing segment
modified
sugar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167009610A
Other languages
English (en)
Korean (ko)
Other versions
KR20160054595A (ko
Inventor
타마르 알. 그로스먼
마이클 엘. 맥칼렙
앤드루 티. 와트
수잔 엠. 프레이어
Original Assignee
아이오니스 파마수티컬즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아이오니스 파마수티컬즈, 인코포레이티드 filed Critical 아이오니스 파마수티컬즈, 인코포레이티드
Publication of KR20160054595A publication Critical patent/KR20160054595A/ko
Application granted granted Critical
Publication of KR102381790B1 publication Critical patent/KR102381790B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21047—Alternative-complement-pathway C3/C5 convertase (3.4.21.47), i.e. properdin factor B
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Epidemiology (AREA)
  • Amplifiers (AREA)
  • Optical Communication System (AREA)
KR1020167009610A 2013-09-13 2014-09-12 보체 인자 b의 조절자 Active KR102381790B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361877624P 2013-09-13 2013-09-13
US61/877,624 2013-09-13
PCT/US2014/055458 WO2015038939A2 (en) 2013-09-13 2014-09-12 Modulators of complement factor b

Publications (2)

Publication Number Publication Date
KR20160054595A KR20160054595A (ko) 2016-05-16
KR102381790B1 true KR102381790B1 (ko) 2022-03-31

Family

ID=52666522

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167009610A Active KR102381790B1 (ko) 2013-09-13 2014-09-12 보체 인자 b의 조절자

Country Status (32)

Country Link
US (5) US20160222389A1 (cg-RX-API-DMAC7.html)
EP (2) EP3043827B1 (cg-RX-API-DMAC7.html)
JP (3) JP6666250B2 (cg-RX-API-DMAC7.html)
KR (1) KR102381790B1 (cg-RX-API-DMAC7.html)
CN (2) CN112359042A (cg-RX-API-DMAC7.html)
AU (2) AU2014318580B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016004671B1 (cg-RX-API-DMAC7.html)
CA (1) CA2921842A1 (cg-RX-API-DMAC7.html)
CL (2) CL2016000606A1 (cg-RX-API-DMAC7.html)
CR (1) CR20160170A (cg-RX-API-DMAC7.html)
DK (1) DK3043827T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2016000063A (cg-RX-API-DMAC7.html)
EA (1) EA035433B1 (cg-RX-API-DMAC7.html)
ES (1) ES2745758T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20191600T1 (cg-RX-API-DMAC7.html)
HU (1) HUE045109T2 (cg-RX-API-DMAC7.html)
IL (1) IL244095A0 (cg-RX-API-DMAC7.html)
LT (1) LT3043827T (cg-RX-API-DMAC7.html)
MA (1) MA38959A1 (cg-RX-API-DMAC7.html)
MX (2) MX371518B (cg-RX-API-DMAC7.html)
MY (1) MY181251A (cg-RX-API-DMAC7.html)
PE (2) PE20160500A1 (cg-RX-API-DMAC7.html)
PH (1) PH12016500443A1 (cg-RX-API-DMAC7.html)
PL (1) PL3043827T3 (cg-RX-API-DMAC7.html)
PT (1) PT3043827T (cg-RX-API-DMAC7.html)
RS (1) RS59252B1 (cg-RX-API-DMAC7.html)
RU (1) RU2662967C2 (cg-RX-API-DMAC7.html)
SG (2) SG11201601445XA (cg-RX-API-DMAC7.html)
SI (1) SI3043827T1 (cg-RX-API-DMAC7.html)
UA (1) UA119046C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015038939A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201601236B (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1991677A2 (en) 2006-01-26 2008-11-19 Isis Pharmaceuticals, Inc. Compositions and their uses directed to huntingtin
ES2526295T5 (es) 2006-10-18 2021-05-04 Ionis Pharmaceuticals Inc Compuestos antisentido
NZ714887A (en) 2009-09-11 2019-07-26 Ionis Pharmaceuticals Inc Modulation of huntingtin expression
EP2673361B1 (en) 2011-02-08 2016-04-13 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
DK2992098T3 (da) 2013-05-01 2019-06-17 Ionis Pharmaceuticals Inc Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression
MY181251A (en) * 2013-09-13 2020-12-21 Ionis Pharmaceuticals Inc Modulators of complement factor b
SG10201804960RA (en) * 2013-12-12 2018-07-30 Alnylam Pharmaceuticals Inc Complement component irna compositions and methods of use thereof
EA036496B1 (ru) * 2014-05-01 2020-11-17 Ионис Фармасьютикалз, Инк. Конъюгированные олигонуклеотиды для модулирования экспрессии фактора комплемента b
WO2017135397A1 (ja) * 2016-02-05 2017-08-10 協和発酵キリン株式会社 補体ｂ因子の発現を抑制するアンチセンスオリゴヌクレオチド
SG11201811491YA (en) 2016-06-27 2019-01-30 Achillion Pharmaceuticals Inc Quinazoline and indole compounds to treat medical disorders
CA3043768A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
WO2018117253A1 (ja) * 2016-12-23 2018-06-28 協和発酵キリン株式会社 補体ｂ因子の発現を抑制する核酸
WO2019027015A1 (ja) * 2017-08-02 2019-02-07 協和発酵キリン株式会社 核酸複合体
SG11202002940QA (en) 2017-11-01 2020-04-29 Alnylam Pharmaceuticals Inc Complement component c3 irna compositions and methods of use thereof
WO2020109343A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Combination therapy for treatment of macular degeneration
WO2021081026A1 (en) 2019-10-22 2021-04-29 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof
JP2023523790A (ja) * 2020-04-30 2023-06-07 アルナイラム ファーマシューティカルズ， インコーポレイテッド 補体因子Ｂ（ＣＦＢ）ｉＲＮＡ組成物およびその使用方法
WO2022028507A1 (zh) 2020-08-07 2022-02-10 上海美悦生物科技发展有限公司 一种杂环类化合物、其制备方法及用途
KR20230049115A (ko) 2020-08-07 2023-04-12 상하이 메이유에 바이오테크 디벨롭먼트 컴퍼니 리미티드 보체 인자 b 억제제 및 이의 약학적 조성물, 제조 방법 및 용도
EP4373940A4 (en) 2021-07-17 2025-10-01 Sirnaomics Inc PRODUCTS AND COMPOSITIONS
WO2023031359A1 (en) 2021-09-02 2023-03-09 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of complement factor b (cfb) in a cell
CN118302525A (zh) 2021-10-29 2024-07-05 阿尔尼拉姆医药品有限公司 补体因子B（CFB）iRNA组合物及其使用方法
AU2022396536A1 (en) 2021-11-24 2024-06-06 Adarx Pharmaceuticals, Inc. Complement factor b-modulating compositions and methods of use thereof
WO2023129496A2 (en) * 2021-12-27 2023-07-06 Apellis Pharmaceuticals, Inc. Rnas for complement inhibition
WO2023143293A1 (zh) 2022-01-26 2023-08-03 上海美悦生物科技发展有限公司 补体因子b抑制剂的盐型、晶型及其制备方法和应用
CA3266935A1 (en) 2022-09-10 2024-03-14 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Piperidine derivatives substituted at position 2, their preparation methods and medicinal uses
WO2024097861A1 (en) * 2022-11-02 2024-05-10 Ionis Pharmaceuticals, Inc. Methods for modulating complement factor b expression
TW202506657A (zh) 2023-04-27 2025-02-16 大陸商上海翰森生物醫藥科技有限公司 一種哌啶基吲哚化合物的鹽及其製備方法
TW202513799A (zh) * 2023-06-02 2025-04-01 大陸商維亞臻生物技術（蘇州）有限公司 用於免疫類疾病的雙鏈核苷酸化合物及其用途
WO2025002299A1 (en) * 2023-06-28 2025-01-02 Shanghai Argo Biopharmaceutical Co., Ltd. Compositions and methods for inhibiting expression of complement factor b (cfb)
WO2025002401A1 (zh) * 2023-06-28 2025-01-02 百奥赛图(北京)医药科技股份有限公司 一种cfb基因修饰的非人动物
WO2025122669A1 (en) * 2023-12-05 2025-06-12 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized complement factor b gene

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000021559A2 (en) * 1998-10-09 2000-04-20 Musc Foundation For Research Development Blocking factor b to treat complement-mediated immune disease
US20050107319A1 (en) 2003-11-19 2005-05-19 Rekha Bansal Method of inhibiting factor B-mediated complement activation, and the uses thereof
US7696344B2 (en) 2002-11-14 2010-04-13 Dharmacon, Inc. siRNA targeting complement factor B

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
FR2567892B1 (fr) 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
DE69034150T2 (de) 1989-10-24 2005-08-25 Isis Pharmaceuticals, Inc., Carlsbad 2'-Modifizierte Oligonukleotide
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
GB9009980D0 (en) 1990-05-03 1990-06-27 Amersham Int Plc Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
ES2116977T3 (es) 1990-05-11 1998-08-01 Microprobe Corp Soportes solidos para ensayos de hibridacion de acidos nucleicos y metodos para inmovilizar oligonucleotidos de modo covalente.
EP0538194B1 (de) 1991-10-17 1997-06-04 Novartis AG Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
FR2687679B1 (fr) 1992-02-05 1994-10-28 Centre Nat Rech Scient Oligothionucleotides.
EP0577558A2 (de) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
JPH08504559A (ja) 1992-12-14 1996-05-14 ハネウエル・インコーポレーテッド 個別に制御される冗長巻線を有するモータシステム
CA2159631A1 (en) 1993-03-30 1994-10-13 Sanofi Acyclic nucleoside analogs and oligonucleotide sequences containing them
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US20080119427A1 (en) 1996-06-06 2008-05-22 Isis Pharmaceuticals, Inc. Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
JP4236812B2 (ja) 1997-09-12 2009-03-11 エクシコン エ／エス オリゴヌクレオチド類似体
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6043352A (en) 1998-08-07 2000-03-28 Isis Pharmaceuticals, Inc. 2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
KR20070118315A (ko) 1999-04-21 2007-12-14 와이어쓰 폴리뉴클레오티드 서열의 기능을 억제하기 위한 조성물
US7053207B2 (en) 1999-05-04 2006-05-30 Exiqon A/S L-ribo-LNA analogues
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
EP1244667B1 (en) 1999-12-30 2006-04-05 K.U. Leuven Research & Development Cyclohexene nucleic acids
CA2452458A1 (en) 2001-07-03 2003-01-16 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
US6964950B2 (en) 2001-07-25 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of C-reactive protein expression
WO2004024749A2 (en) * 2002-09-13 2004-03-25 Invitrogen Corporation Thermostable reverse transcriptases and uses thereof
WO2004041889A2 (en) 2002-11-05 2004-05-21 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
AU2003291755A1 (en) 2002-11-05 2004-06-07 Isis Pharmaceuticals, Inc. Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
US6673661B1 (en) 2002-12-20 2004-01-06 Taiwan Semiconductor Manufacturing Co., Ltd. Self-aligned method for forming dual gate thin film transistor (TFT) device
US20070123466A1 (en) * 2003-05-13 2007-05-31 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method of treating recurrent miscarriages
EP1661905B9 (en) 2003-08-28 2012-12-19 IMANISHI, Takeshi Novel artificial nucleic acids of n-o bond crosslinkage type
CA2538252C (en) 2003-09-18 2014-02-25 Isis Pharmaceuticals, Inc. 4'-thionucleosides and oligomeric compounds
BRPI0506629A (pt) 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
WO2005116204A1 (ja) * 2004-05-11 2005-12-08 Rnai Co., Ltd. Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法
US7919472B2 (en) 2004-09-17 2011-04-05 Isis Pharmaceuticals, Inc. Enhanced antisense oligonucleotides
WO2006047842A2 (en) 2004-11-08 2006-05-11 K.U. Leuven Research And Development Modified nucleosides for rna interference
GB0521716D0 (en) * 2005-10-25 2005-11-30 Genomica Sau Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases
WO2007090071A2 (en) 2006-01-27 2007-08-09 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
AU2007249349B2 (en) 2006-05-11 2012-03-08 Isis Pharmaceuticals, Inc. 5'-Modified bicyclic nucleic acid analogs
AU2007299705B2 (en) * 2006-09-22 2012-09-06 Dharmacon, Inc. Duplex oligonucleotide complexes and methods for gene silencing by RNA interference
CN101589143A (zh) * 2006-11-27 2009-11-25 Isis药物公司 用于治疗高胆固醇血症的方法
WO2008101157A1 (en) 2007-02-15 2008-08-21 Isis Pharmaceuticals, Inc. 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
JP5332064B2 (ja) * 2007-03-01 2013-11-06 ウェルスタット イムノセラピューティクス， エルエルシー 炎症により特徴付けられる疾患の治療
CA2688321A1 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
DK2173760T4 (en) 2007-06-08 2016-02-08 Isis Pharmaceuticals Inc Carbocyclic bicyclic nukleinsyreanaloge
AU2008272918B2 (en) 2007-07-05 2012-09-13 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
NZ591057A (en) * 2008-07-10 2012-11-30 Az Univ Amsterdam Complement antagonists and uses thereof
DK2361256T3 (da) 2008-09-24 2013-07-01 Isis Pharmaceuticals Inc Cyclohexenyl-nukleinsyreanaloger
EP2601204B1 (en) 2010-04-28 2016-09-07 Ionis Pharmaceuticals, Inc. Modified nucleosides and oligomeric compounds prepared therefrom
EP2595663A4 (en) * 2010-07-19 2014-03-05 Isis Pharmaceuticals Inc MODULATION OF DYSTROPHIA MYOTONICA PROTEIN KINASE (DMPK) EXPRESSION
CN103547588B (zh) * 2011-04-13 2016-06-29 Isis制药公司 Ptp1b表达的反义调节
MY181251A (en) * 2013-09-13 2020-12-21 Ionis Pharmaceuticals Inc Modulators of complement factor b
EA036496B1 (ru) * 2014-05-01 2020-11-17 Ионис Фармасьютикалз, Инк. Конъюгированные олигонуклеотиды для модулирования экспрессии фактора комплемента b

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000021559A2 (en) * 1998-10-09 2000-04-20 Musc Foundation For Research Development Blocking factor b to treat complement-mediated immune disease
US7696344B2 (en) 2002-11-14 2010-04-13 Dharmacon, Inc. siRNA targeting complement factor B
US20050107319A1 (en) 2003-11-19 2005-05-19 Rekha Bansal Method of inhibiting factor B-mediated complement activation, and the uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NCBI 서열, AK130533.1 (2006.09.14.) 1부.*

Also Published As

Publication number Publication date
CN112359042A (zh) 2021-02-12
AU2014318580A1 (en) 2016-03-03
EP3043827A2 (en) 2016-07-20
JP7297112B2 (ja) 2023-06-23
WO2015038939A2 (en) 2015-03-19
ZA201601236B (en) 2017-05-31
US20190048351A1 (en) 2019-02-14
JP7158363B2 (ja) 2022-10-21
CR20160170A (es) 2016-07-15
RU2016113763A (ru) 2017-10-16
MX2016003263A (es) 2016-12-08
RU2662967C2 (ru) 2018-07-31
PE20160500A1 (es) 2016-05-21
PL3043827T3 (pl) 2020-03-31
MX371518B (es) 2020-01-31
MA38959A1 (fr) 2017-08-31
DK3043827T3 (da) 2019-08-26
PH12016500443A1 (en) 2016-05-16
SI3043827T1 (sl) 2019-08-30
US20240247268A1 (en) 2024-07-25
EP3043827B1 (en) 2019-07-03
DOP2016000063A (es) 2016-06-01
MX2020001258A (es) 2020-03-20
MY181251A (en) 2020-12-21
AU2014318580B2 (en) 2019-12-12
US20200149047A1 (en) 2020-05-14
EP3603677A1 (en) 2020-02-05
KR20160054595A (ko) 2016-05-16
ES2745758T3 (es) 2020-03-03
CL2018002334A1 (es) 2018-12-14
HUE045109T2 (hu) 2019-12-30
HK1225638A1 (en) 2017-09-15
JP2022058784A (ja) 2022-04-12
EP3043827A4 (en) 2017-05-24
JP6666250B2 (ja) 2020-03-13
PE20190354A1 (es) 2019-03-07
HRP20191600T1 (hr) 2019-11-29
BR112016004671B1 (pt) 2020-12-29
CL2016000606A1 (es) 2017-02-17
LT3043827T (lt) 2019-08-12
SG10201806787VA (en) 2018-09-27
IL244095A0 (en) 2016-04-21
US20160222389A1 (en) 2016-08-04
CA2921842A1 (en) 2015-03-19
US11926830B2 (en) 2024-03-12
JP2016533765A (ja) 2016-11-04
US20220243209A1 (en) 2022-08-04
PT3043827T (pt) 2019-09-26
WO2015038939A3 (en) 2015-07-02
JP2020036600A (ja) 2020-03-12
EA035433B1 (ru) 2020-06-15
RS59252B1 (sr) 2019-10-31
EA201690582A1 (ru) 2016-07-29
CN105744959B (zh) 2020-12-01
CN105744959A (zh) 2016-07-06
UA119046C2 (uk) 2019-04-25
AU2020201763A1 (en) 2020-04-02
SG11201601445XA (en) 2016-03-30

Similar Documents

Publication Publication Date Title
KR102381790B1 (ko) 보체 인자 b의 조절자
KR102369736B1 (ko) 보체 인자 b 발현을 조절하기 위한 조성물 및 방법
JP7289347B2 (ja) Ｐｃｓｋ９発現のモジュレーター
TW201723176A (zh) Ｋｒａｓ表現之調節劑
CN114728017B (zh) Pnpla3表达的调节剂
AU2014312196A1 (en) Modulation of prekallikrein (PKK) expression
TW202016305A (zh) Ａｐｏｌ１表現之調節劑
HK1225638B (en) Modulators of complement factor b
HK40022442A (en) Modulators of complement factor b
HK1234433A1 (en) Compositions and methods for modulating complement factor b expression
HK1234433B (en) Compositions and methods for modulating complement factor b expression

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160412

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190911

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200807

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20210323

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220105

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220329

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220329

End annual number: 3

Start annual number: 1

PG1601 Publication of registration